blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3218399

EP3218399 - BISPECIFIC ANTIBODIES AND METHODS OF USE IN OPHTHALMOLOGY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  30.09.2022
Database last updated on 16.11.2024
FormerExamination is in progress
Status updated on  17.08.2018
FormerRequest for examination was made
Status updated on  18.08.2017
FormerThe international publication has been made
Status updated on  29.03.2017
Most recent event   Tooltip30.09.2022Application deemed to be withdrawnpublished on 02.11.2022  [2022/44]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2017/38]
Inventor(s)01 / BEDOUCHA, Marc
7 rue des Sources
F-68220 Ranspach-le-Haut / FR
02 / BREUER, Sebastian
Haselbergstrasse 6
82377 Penzberg / DE
03 / DENGL, Stefan
Schleissheimer Strasse 44a
80333 Muenchen / DE
04 / GASSNER, Christian
Habichtweg 4
82377 Penzberg / DE
05 / GEORGES, Guy
Am Berggraben 11
Habach 82392 / DE
06 / GRUENER, Sabine
Solvayplatz 26E
79639 Grenzach-Wyhlen / DE
07 / HARTMANN, Guido
Hangstrasse 34
79539 Loerrach / DE
08 / HUELSMANN, Peter Michael
Im Sonnental 20
82392 Habach / DE
09 / KETTENBERGER, Hubert
Passauer Strasse 30
81369 Muenchen / DE
10 / MOELLEKEN, Joerg
Ossietzkystrasse 2
80686 Muenchen / DE
11 / MOLHOJ, Michael
Fachnerstrasse 7A
80686 Muenchen / DE
12 / MUNDIGL, Olaf
Tassiloring 16
82362 Weilheim / DE
13 / REGULA, Joerg Thomas
Innerkoflerstrasse 17 B
81377 Muenchen / DE
14 / SCHUMACHER, Ralf
Hochfeldstrasse 37
82377 Penzberg / DE
15 / WEISER, Barbara
Koenigbergstrasse 51
82404 Sindelsdorf / DE
 [2017/39]
Former [2017/38]01 / BEDOUCHA, Marc
7 rue des Sources
F-68220 Ranspach-le-Haut / FR
02 / BREUER, Sebastian
Haselbergstrasse 6
82377 Penzberg / DE
03 / DENGL, Stefan
Schleissheimer Strasse 44a
80333 Muenchen / DE
04 / GASSNER, Christian
Habichtweg 4
82377 Penzberg / DE
05 / GEORGES, Guy
Am Berggraben 11
Habach 82392 / DE
06 / GRUENER, Sabine
Solvaystrasse 10
79639 Grenzach-Wyhlen / DE
07 / HARTMANN, Guido
Hangstrasse 34
79539 Loerrach / DE
08 / HUELSMANN, Peter Michael
Im Sonnental 20
82392 Habach / DE
09 / KETTENBERGER, Hubert
Passauer Strasse 30
81369 Muenchen / DE
10 / MOELLEKEN, Joerg
Ossietzkystrasse 2
80686 Muenchen / DE
11 / MOLHOJ, Michael
Fachnerstrasse 7A
80686 Muenchen / DE
12 / MUNDIGL, Olaf
Tassiloring 16
82362 Weilheim / DE
13 / REGULA, Joerg Thomas
Innerkoflerstrasse 17 B
81377 Muenchen / DE
14 / SCHUMACHER, Ralf
Hochfeldstrasse 37
82377 Penzberg / DE
15 / WEISER, Barbara
Koenigbergstrasse 51
82404 Sindelsdorf / DE
Representative(s)Burger, Alexander, et al
Roche Diagnostics GmbH
Patentabteilung
Nonnenwald 2
82377 Penzberg / DE
[N/P]
Former [2017/38]Burger, Alexander, et al
Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52
82372 Penzberg / DE
Application number, filing date15790946.606.11.2015
[2017/38]
WO2015EP75879
Priority number, dateEP2014019251710.11.2014         Original published format: EP 14192517
[2017/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016075037
Date:19.05.2016
Language:EN
[2016/20]
Type: A1 Application with search report 
No.:EP3218399
Date:20.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application.
[2017/38]
Search report(s)International search report - published on:EP19.05.2016
ClassificationIPC:C07K16/22
[2017/38]
CPC:
C07K16/245 (EP,CN,KR,US); C07K16/22 (EP,CN,KR,US); A61P27/02 (EP);
A61P27/06 (EP); A61P27/08 (EP); C07K16/2863 (CN);
A61K2039/505 (CN,KR); C07K2317/24 (US); C07K2317/31 (EP,CN,KR,US);
C07K2317/33 (US); C07K2317/35 (US); C07K2317/52 (US);
C07K2317/522 (US); C07K2317/55 (EP,KR,US); C07K2317/56 (US);
C07K2317/60 (CN); C07K2317/62 (EP,KR,US); C07K2317/76 (CN,US);
C07K2317/92 (EP,KR,US); C07K2317/94 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/38]
TitleGerman:BISPEZIFISCHE ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG IN DER OPHTHALMOLOGIE[2017/38]
English:BISPECIFIC ANTIBODIES AND METHODS OF USE IN OPHTHALMOLOGY[2017/38]
French:ANTICORPS BISPÉCIFIQUES ET PROCÉDÉS D'UTILISATION EN OPHTALMOLOGIE[2017/38]
Entry into regional phase12.06.2017National basic fee paid 
12.06.2017Designation fee(s) paid 
12.06.2017Examination fee paid 
Examination procedure29.03.2017Amendment by applicant (claims and/or description)
29.03.2017Date on which the examining division has become responsible
12.06.2017Examination requested  [2017/38]
16.08.2018Despatch of a communication from the examining division (Time limit: M06)
05.02.2019Reply to a communication from the examining division
19.03.2020Despatch of a communication from the examining division (Time limit: M06)
22.12.2020Reply to a communication from the examining division
01.06.2022Application deemed to be withdrawn, date of legal effect  [2022/44]
24.06.2022Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2022/44]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
22.12.2020Request for further processing filed
22.12.2020Full payment received (date of receipt of payment)
Request granted
10.02.2021Decision despatched
Fees paidRenewal fee
08.11.2017Renewal fee patent year 03
08.11.2018Renewal fee patent year 04
14.11.2019Renewal fee patent year 05
10.11.2020Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.11.202107   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2005087812  (LUDWIG INST CANCER RES [US], et al) [Y] 1-14 * pg. 46, line 28 to pg. 48, line 1; claim 1 *;
 [Y]WO2008024188  (ABBOTT LAB [US], et al) [Y] 1-14 * examples 1.3-1.8 *;
 [Y]WO2011117329  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-14 * page 37, paragraph 1 - paragraph 2; examples 1-11 *;
 [Y]WO2014001442  (MOLECULAR PARTNERS AG [CH]) [Y] 1-14 * page 27, paragraph final; claim 26 *;
 [Y]WO2014072876  (PFIZER [US]) [Y] 1-14 * page 1 * * page 82, line 26 - page 85 *;
 [Y]WO2014177460  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-14 * page 9, line 10 - line 27 * * page 43, line 3 - line 7 * * page 61, line 11 - line 29 * * page 1; examples 1-8 *;
 [Y]  - W. SCHAEFER ET AL, "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20110705), vol. 108, no. 27, doi:10.1073/pnas.1019002108, ISSN 0027-8424, pages 11187 - 11192, XP055003817 [Y] 6,8 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.1019002108
 [Y]  - Y. KIENAST ET AL, "Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy", CLINICAL CANCER RESEARCH, (20131004), vol. 19, no. 24, doi:10.1158/1078-0432.CCR-13-0081, ISSN 1078-0432, pages 6730 - 6740, XP055106066 [Y] 6,8 * abstract * * page 6731, column right *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0081
 [A]  - ROLAND KONTERMANN, "Dual targeting strategies with bispecific antibodies", MABS, LANDES BIOSCIENCE, US, (20120301), vol. 4, no. 2, doi:10.4161/MABS.4.2.19000, ISSN 1942-0870, pages 182 - 197, XP009160769 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.4161/mabs.4.2.19000
 [Y]  - WU CHENGBIN ET AL, "Molecular construction and optimization of anti-human IL-1 alpha/beta dual variable domain immunoglobulin (DVD-Ig (TM)) molecules", MABS, LANDES BIOSCIENCE, US, (20090701), vol. 1, no. 4, ISSN 1942-0862, pages 339 - 347, XP002657321 [Y] 1-14 * abstract, table 3, pg. 346, lhc, §1 *
 [Y]  - QINGCUI LI ET AL, "Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model", INTERNATIONAL IMMUNOPHARMACOLOGY, (20140701), vol. 21, no. 1, doi:10.1016/j.intimp.2014.04.018, ISSN 1567-5769, pages 119 - 127, XP055195879 [Y] 1-14 * abstract and pgs. 122-123 *

DOI:   http://dx.doi.org/10.1016/j.intimp.2014.04.018
 [Y]  - MABRY ROBERT ET AL, "A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.", MABS 2010 JAN-FEB, (201001), vol. 2, no. 1, ISSN 1942-0870, pages 20 - 34, XP055196572 [Y] 1-14 * page 26, paragraph bridging - page 27; table 1 * * examples 1-12 * * page 20, column left, paragraph final *

DOI:   http://dx.doi.org/10.4161/mabs.2.1.10498
 [Y]  - JO NOBUO ET AL, "Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular enclothelial growth factor therapy in multiple models of ocular neovascularization", AMERICAN JOURNAL OF PATHOLOGY; [10640], ELSEVIER INC, US, (20060601), vol. 168, no. 6, doi:10.2353/AJPATH.2006.050588, ISSN 0002-9440, pages 2036 - 2053, XP002500820 [Y] 1-14 * abstract *

DOI:   http://dx.doi.org/10.2353/AJPATH.2006.050588
 [Y]  - LEONARDZEHR, "Molecular Partners Continues to validate DARPin platform", INTERNET CITATION, (20120911), pages 1 - 8, URL: http://biotuesdays.com/2012/09/11/molecular-partners-continues-to-validate-darpin-platform/, (20130829), XP002711999 [Y] 1-14 * the whole document *
ExaminationWO2015150447
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.